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ABSTRACT 
From the chloroform extract of the stem bark of Acacia ataxacantha, a ferrulic acid derivative identified as n-tetradecanyl-3-
methoxy-4-hydroxy –trans-cinnamate (tetradecanyl ferulate) compound 2 was isolated for the first time from this plant alongside 
the triterpene lupenol. The structure of compound 2 was confirmed using NMR and MS and is reported here for the first time. 
Primary activity of the isolated compound against a panel of disease related protein kinases reveal the compound to be in-active.  
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INTRODUCTION 
 
Natural products and or natural product structures have 
continued to play a significant role in drug discovery and 
development process (Newmann and Cragg, 2016). Plants 
have continued to be a source of medicine especially in the 
developing parts of the world where about 80% of the 
population depend on natural products for their health needs 
(Rates, 2001; Calixto, 2000; Raskin et al., 2002). This has 
necessitated intensive studies into bioactive secondary 
metabolites using methods such as extraction, isolation, 
purification and chemical characterization of plant extracts 
which could unfold a novel chemical compounds suitable for 
drug development (Butler et al, 2004; Lahlou et al, 2007 
Ebada et al, 2008).The therapeutic efficacy of medicinal 
plants in combating diseases lies in presence of 
Phytoconstituents present in them. These include alkaloids, 
flavonoids, steroids and saponins among others (Harbone, 
1998; Busse, 2000; Newmann et al, 2000). Plants used as 
medicines have been considered safe, less toxic and also as a 
source of fantastic biomolecules unequalled by any synthetic 
procedure (Katiyar et al, 2012).  
Human protein kinases represent the third largest enzyme 
class and are responsible for modifying an estimated one-third 
of human proteome (Manning et al,2002).It has been firmly 
demonstrated that hyperactivation, hyperproduction or 
mutations of these kinases leading to the disruption  of cell 
signalling cascades, play important role in several diseases 
such as cancer, inflammation, diabetes among others, thus 
making protein kinases one of the most important targets for 
pharmaceutical industry (Capedeville et al, 2002). The human 
genome consists of over 517 protein kinases that include two 
sub families, serine/threonine and tyrosine kinases 
(Capedeville et al, 2002). Numerous tyrosine kinases 
inhibitors have been discovered by screening plant extracts 
based on ethnopharmacological and chemotaxonomic 
knowledge (Hollosyl and Keri, 2004). Specific screening 
approach have led to the isolation of structurally distinct 
classes of inhibitors which have served as leads for further 
design and synthesis of more active analogues. 
Acacia is a large genus of the family fabaceae, with about 
1,400 species. Most of the species belonging to the genus are 
rich in secondary metabolites containing mainly tannins, 
flavonoids and gums (Seigler, 2003), and is widely distributed 
in tropical and non-tropical countries including Nigeria. 
Acacia ataxacantha is wide spread in sub Saharan Africa 
including Nigeria, Benin and Kenya where various parts of the 
plant has ethnomedicnal applications in relieving ailments 
such as dysentery, cough, joint pains and pneumonia(Mac 
Donald et al,2010;Kareji,2013). The antioxidant, antifungal 
and antibacterial activity of the bark extracts have been 
reported (Amoussa et al, 2015 a,b). Phytochemically, 
triterpenoids and a new chromone have been reported by 
(Amoussa et al, 2016, a b). As part of our continuing studies 
of the genus Acacia, for protein kinase inhibitory constituents, 
we report herein the isolation of a ferrulic acid ester from the 
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chloroform extract of the stem bark of Acacia ataxacantha and 
the primary screening of the compound against a panel of 
disease related protein kinases. 
 
MATERIALS AND METHODS 
 
Column chromatography was performed on silica gel G 200-
400 mesh (Silicycle),Thin layer chromatography was 
performed on pre-coated TLC plate silica gel (0.2 mm) 
aluminum backed (Silicycle). UV spectrum was performed on 
Pye-Unicam UV Spectrophotometer. IR spectra were 
recorded on an Agilent 2346, Infra-Red spectrophotometer in 
Kbr. NMR spectra (1H and 13C) were performed on a Bruker 
DRX 400 spectrophotometer (400MHz for 1H and 125MHz 
for 13C) in CDCl3 using TMS as internal solvent and high 
resolution mass spectrometry was carried out using an ESI-
LTQ-orbitrap Discovery XL mass spectrometry (Thermo 
Scientific, Germany). 
 
Plant material 
The stem bark of Acacia ataxacantha was collected in Zaria in 
the month of August and authenticated at the herbarium 
section, Biological Science Department, Ahmadu Bello 
University, Zaria-Nigeria, was a voucher specimen (900290) 
was deposited in the herbarium. 
 
Extraction and Isolation 
The powdered bark of the plant (250 g) was extracted at room 
temperature to exhaustion using maceration with 2.5L of 
chloroform; the combined chloroform extract was 
concentrated to give a brownish mass (2.3 g). The marc was 
then extracted with 2x 2.5 L of 70% ethanol and the combined 
ethanol extract after the removal of the solvent using rotary 
evaporator gave 17.2 g of ethanol extract.  1.8 g of the 
chloroform extract of the bark of Acacia ataxacantha was 
packed in a column (1.9cm x 42cm) and eluted gradiently with 
n-hexane and n-hexane ethylacetate mixtures. The progress of 
separation were monitored on TLC using the solvent systems 
N-hexane:ethylacetate (9:1; 5:1 and 3:1).  Fractions eluted 
with 5% ethylacetate in n-hexane afforded from 4 pooled 
fractions (25 ml) and removal of the solvent afforded 
compound 1, a white solid (7 mg). Fractions eluted with 20% 
ethylacetate in n-hexane afforded from the pooled fractions 
(20 ml) upon removal of the solvent a pale yellow solid which 
was re-purified over sephadex LH-20 eluted with 5% n-
hexane in dichloromethane to give compound 2, a white solid 
(9 mg). 
 
Protein Kinase inhibitory studies 
Compound 2 was screened against a panel of disease related 
protein kinases. Kinase activity were assayed in appropriate 
buffer, with either protein or peptide as substrate in the 
presence of 15 µM [Ɣ-33P]ATP (3,000 Ci/mmol, 10mCi/ml) 
in a final volume of 30 µl following the assay described by 
(Bach et al, 2005). Controls were performed with appropriate 
dilutions of dimethyl sulphoxide. Full length kinases were 
used unless specified.  
 
RESULTS 
 
Compound 1 was found to be Lupenol by comparison of its 
spectral properties (1H and 13C-NMR and MS) with literature 
data (Privitea and Monaco, 1984; Connolly and Hill, 1999) 
and as previously reported from this plant (Ahmadu et al, 
2018). 
Compound 2, a white solid (9 mg). UV (CHCl3): λmax.  235, 
318nm 
IR(KBr):cm-1: 3444; 2852; 1737; 1682; 1639; 1599; 1451-
1376; 1073; 1043 and 722. 
1H-NMR (CDCl3): δ (ppm),7.63 (1H, d,J=17Hz),7.10 (1H, 
d,d,J=2,8.5Hz), 7.05 (1H,d,J= 2Hz, 6.85 (1H,d,J=8.5Hz), 5.85 
(1H, s), 5.2 (1H,s),4.21 (2H, t, OCH2), 3.90 (3H,s,OCH3), 1.55 
(m),1.25 (10H, s), 0.90 (3H, t, J = 6.8Hz)  
13C-NMR (CDCl3): δ (ppm): 179.5, 167.5, 147.9, 144.7, 
127.0, 123.1, 115.6, 114.7, 109.2, 64.5, 55.9, 34.0, 32.0, 29.7, 
29.4, 27.2, 26.0, 24.7, 22.7 and 14.2 
HR-EI-MS: m/z 392.2322 (M++2)), 391.2298(M++H), 
377.2144, 194.1112, 177.2013  
 
 
Figure 1 
Compound 2,R1=H;R2=Me;R3=-CH2 (CH2)12CH3 
 
Table 1 shows the results of the primary screening performed 
using 50 µg/ml of compound 1. Data are expressed in 
percentage of maximal activity measured in the absence of the 
inhibitor. ATP concentration used in the kinase activity was 
15 µM (values are mean: n=2). Kinases are from human (Hs- 
Homosapiens; Ssc: Sus Scrofa; Rn: Ratus norvegicus; Mm: 
Mus musculus; Pf: Plasmodium falciparum; Lm: Leishmania 
major; Ld: Leishmania donovani. 
 
 
Table 1  
Primary activity of compound 2 against disease related Protein kinase# 
Compound HsCdk2 HsCdk5 HsCdk9 MmCLK1 SscGSK3 RnDYyrk1A PIM1 Haspine SscCK1 LmCK1 Hs AURK B 
1 76.0 70.0 68.0 48.0 66.0 63.0 84.0 108.0 45.0 71.0 76.0 
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DISCUSSION 
 
Compound 1, was isolated as a white solid, its spectral 
properties (NMR and MS) are in agreement with the literature 
data of Lupenol (Chaturvedula and Indira, 2012). 
 Compound 2, was isolated as a pale white solid. High 
resolution ESI-MS gave an (M+1) peak at 391.2298 which 
points to a molecular formula C24H38O4, indicating six degrees 
of unsaturation. The diagnostic fragment peaks at m/z 177 and 
194 are both characteristic of a methoxy and hydroxyl-
substituted cinnamic moiety (Achenback et al, 1986). The 
presence of double bond was evident from the IR bands at 
1639,1599cm-1, while a carbonyl band of an ester appeared at 
1737cm-1. 
 The UV spectrum gave λmax at 235 and 318nm typical 
of ferrulic acid ester (Delazar et al, 2004)). The proton NMR 
spectrum in CDCl3 revealed a typical ABX spin at system at 
δ 6.85(d, J=8.5Hz), 7.10 (d, d  ,J=2, 8.5Hz) and 7.05(d,J=2Hz) 
indicating the presence of three aromatic protons with 
ortho,ortho/meta and meta coupling respectively. The 
presence of a trans double bond was confirmed by signals at δ 
6.27 d (J=17Hz and 7.63 d (J=17Hz) respectively, while an 
oxymethylene and methoxy protons at δH 4.21 (t) and 3.90(s) 
revealed the compound to be a ferulic acid ester, a 
tetradecanoyl moiety was evident with the signals at (δ=0.9,t, 
J=6.8Hz;1.25,s, (CH2X8), 4.21,t, J=6.8 Hz). The deshielded 
nature of the oxymethylene signal at δ=4.21 (t) confirmed its 
link to the carbonyl of the ferulic acid moiety and thus 
provided evidence for the ester formation (Delazar et al, 
2004), a long chain methylene signal at δ=1.25 (s) was also 
evident from the 1H-NMR spectrum. The 13C-NMR spectral 
data further confirmed the presence of ferulic ester moiety 
with ester carbonyl at δ=167.7 ppm, methoxyl signal at δ=55.9 
ppm, oxymethylene carbon at δ=64.5 and methyl carbon at 
δ=14.1 ppm respectively.  
 The 13C-NMR spectral data assignment was further 
resolved through the DEPT 135 experiment into four 
quaternary carbons at δ=167.5,147.9,146.8 and 127.0 ppm 
assigned to (C-9, C-4,C-3 and C-1) of the ferulic acid moeity, 
5 methine carbons at δ=144.7,123.08,115.62,114.64,109.23, 
were  assigned to (C-7,C-6,C-2,C-5 and C-8),while the methyl 
and methoxy carbons were evident from the DEPT 135 
spectral which depicted the signals at δ=55.9 and 14.2 ppm 
respectively. The oxymethylene carbon at δ=64.67 ppm was 
also confirmed through the DEPT experiments, while the long 
chain methylene carbon signal was confirmed at δ=29.7 ppm. 
The ferullic acid moiety of compound 2 compared very well 
with a similar ferulic acid ester reported by (Delazar et al, 
2004). All the spectral data of compound 2 compares very well 
with the only report in the literature of this compound reported 
by (Nkengfack et al,1997) from Erythina species. This is the 
first report of this long chain ferulic acid ester from the genus 
Acacia. Compound 2 was screened for primary activity 
against a panel of disease related protein kinases (Table 1), the 
result revealed the activity that remains in the tube after 
treating the kinases with 50 µg/ml of compound 2 compared 
to the control assay that was treated with DMSO. The result 
indicated that compound 2 was not active against most of the 
kinases for example against PIM 1; it shows only 16% of the 
kinase activity, while the highest activity was against CK1 
which gave 55% inhibition of the enzyme activity. This result 
revealed that compound 2 is inactive against the protein 
kinases investigated because most of the activity of the 
compound which gave less than 50% of the kinase activity 
remaining in the tube is only two, against CLK1 and CK1 out 
of the eleven protein kinases investigated. 
 In conclusion, ferulic acid ester was isolated for the first 
time from this plant and protein kinase inhibitory study 
revealed it to be in-active against the disease related kinases 
investigated 
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